Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- 1 September 2011
- journal article
- practice guideline
- Published by Elsevier in Annals of Oncology
- Vol. 22 (suppl_6) , vi25-vi30
Abstract
Breast cancer is the most common cancer in women in many countries, including developing countries. In 2006, the crude incidence in the European Union was 109.8/100 000, and the mortality was 38.4/100 000 women/year. In 2008, 1.38 million new cases and 458 000 breast cancer deaths were noted in the world. Since 1990 the incidence rate has increased 1.5% annually. Due to advances both in early detection and in adjuvant treatment, mortality rates from breast cancer have been decreasing steadily in most Western countries since the early 1990s. However, it is still the leading cause of cancer mortality in women. Approximately 4–6% of breast cancers are metastatic at diagnosis; of those approximately one-fifth will survive 5 years. Depending on prognostic factors, in the worst-case scenario, up to 30% of node-negative and up to 70% of node-positive breast cancers will relapse. The prevalence of metastatic disease is high because many women live with the disease for several years.Keywords
This publication has 23 references indexed in Scilit:
- Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008International Journal of Cancer, 2010
- Coprescription of Tamoxifen and Medications That Inhibit CYP2D6Journal of Clinical Oncology, 2010
- International Guidelines for Management of Metastatic Breast Cancer: Can Metastatic Breast Cancer Be Cured?JNCI: Journal of the National Cancer Institute, 2010
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast CancerJournal of Clinical Oncology, 2009
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM StudyJournal of Clinical Oncology, 2009
- International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent ChemotherapyJNCI: Journal of the National Cancer Institute, 2009
- Imaging bone metastases in breast cancer: techniques and recommendations for diagnosisThe Lancet Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined With Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Administered As First-Line Treatment: The M77001 Study GroupJournal of Clinical Oncology, 2005